How to Get Addyi (Flibanserin) in New Mexico

What Is Flibanserin and Why Does It Require a Prescription?

Flibanserin is the only FDA-approved non-hormonal drug for hypoactive sexual desire disorder in premenopausal women. The FDA granted approval in August 2015 after Sprout Pharmaceuticals submitted data from three Phase 3 trials showing statistically significant improvements in satisfying sexual events (SSEs) and desire scores [1]. Because the drug carries a boxed warning about hypotension and syncope when combined with alcohol or moderate-to-strong CYP3A4 inhibitors, it is prescription-only and was initially distributed under a Risk Evaluation and Mitigation Strategy (REMS) [2]. The REMS requirement was removed by the FDA in April 2019, which meaningfully broadened prescriber access [3].

HSDD affects roughly 10% of adult women in the United States, based on data from the National Health and Social Life Survey and subsequent population studies [4]. The condition is defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria as persistently low sexual desire causing marked distress or interpersonal difficulty, and it is not better explained by another mental disorder, medication, or medical condition [5]. Getting an accurate diagnosis matters before starting flibanserin, because the drug targets the central serotonin-dopamine-norepinephrine pathways and is not indicated for situational or relationship-driven low desire.

The BEGONIA trial (N=949, published J Sex Med 2014) compared flibanserin 100 mg nightly to placebo over 24 weeks and found a statistically significant increase in SSEs (P<0.001) alongside improvements in the Female Sexual Function Index desire domain score [6]. That trial was one of three key studies supporting the August 2015 FDA label.

Is Telehealth Prescribing of Addyi Legal in New Mexico?

Yes. New Mexico explicitly permits telehealth prescribing of controlled and non-controlled medications after a clinically appropriate evaluation, provided the prescriber holds an active New Mexico license or is authorized to practice across state lines through applicable interstate compacts [7]. Flibanserin is not a controlled substance, so the prescribing rules are less restrictive than those for stimulants or opioids.

The New Mexico Medical Board and the New Mexico Board of Nursing both recognize audio-video encounters as sufficient to establish a patient-provider relationship for the purpose of prescribing Schedule IV and unscheduled drugs [8]. A prescriber does not need to conduct an in-person physical exam before writing a flibanserin prescription, as long as the clinical evaluation is thorough enough to establish a diagnosis of HSDD and screen for contraindications.

Practical implication: a New Mexico patient can complete her entire Addyi intake process, including the intake questionnaire, the video consultation, and the prescription transmission to a pharmacy, without leaving home. Several national telehealth platforms operate in New Mexico and list flibanserin as a medication they prescribe. HealthRX clinicians licensed in New Mexico can complete this evaluation asynchronously or via live video.

What Does the Clinical Evaluation Include?

A flibanserin evaluation is not simply a questionnaire. A thorough intake screens for alcohol use (the boxed warning involves severe hypotension and syncope when flibanserin is taken with alcohol) [2], concurrent medications that inhibit CYP3A4 (including fluconazole, ketoconazole, and some macrolide antibiotics), and concurrent use of CNS depressants. The prescriber will also screen for liver impairment, because flibanserin is contraindicated in patients with hepatic insufficiency based on pharmacokinetic data in the FDA label [1].

The Decreased Sexual Desire Screener (DSDS) is a validated four-item tool used by many clinicians to quickly differentiate generalized HSDD from situational low desire [9]. A positive DSDS result, combined with distress scoring using the Female Sexual Distress Scale-Revised (FSDS-R), helps confirm the diagnosis [10]. Scores on the FSDS-R of 11 or higher typically indicate clinically meaningful distress [10].

No blood work is required by the FDA label before starting flibanserin. However, many prescribers order a basic metabolic panel and liver function tests (AST, ALT, bilirubin) at baseline to rule out subclinical hepatic impairment, particularly in patients who report regular alcohol use. A thyroid-stimulating hormone (TSH) level may also be checked to exclude hypothyroidism as a reversible cause of low libido [11]. These labs are not mandatory but represent a reasonable standard of care.

Who Can Prescribe Flibanserin in New Mexico?

Under New Mexico law, flibanserin may be prescribed by any licensed practitioner with prescriptive authority, including MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) [8]. New Mexico is a full-practice-authority state for NPs, meaning certified nurse practitioners can independently evaluate patients, diagnose HSDD, and prescribe Addyi without physician oversight or a collaborative practice agreement [12].

PAs in New Mexico practice under a supervision agreement with a physician, but that agreement does not restrict the specific medications a PA may prescribe as long as those medications are within the PA's scope of practice and the supervising physician's specialty [13]. Flibanserin falls well within scope for any PA practicing in women's health, primary care, or gynecology.

Certified nurse midwives (CNMs) who hold prescriptive authority in New Mexico may also prescribe flibanserin for patients within their practice scope [12]. The American College of Obstetricians and Gynecologists (ACOG) has published guidance encouraging ob-gyns and women's health providers to screen for HSDD as part of routine well-woman care [14].

How to Get a Flibanserin Prescription in New Mexico: Step by Step

Getting a prescription follows a predictable sequence regardless of whether the encounter is telehealth or in-person.

Step 1. Choose a provider. Identify a New Mexico-licensed prescriber or a telehealth platform operating in New Mexico. HealthRX offers licensed clinical providers in New Mexico who specialize in women's sexual health.

Step 2. Complete the intake forms. Expect questions about sexual history, distress duration, relationship context, alcohol use, current medications, and liver health. Be specific. Vague answers slow the evaluation.

Step 3. Attend the consultation. The video or in-person visit typically lasts 15-30 minutes. The prescriber will confirm the HSDD diagnosis, review contraindications, and counsel you on the alcohol restriction before writing the prescription.

Step 4. Select a pharmacy. Your prescriber will send the prescription electronically to a pharmacy of your choice. Options include national mail-order pharmacies, local retail pharmacies in New Mexico, and 503A compounding pharmacies licensed in the state (see below).

Step 5. Obtain the medication. Brand Addyi through mail-order pharmacies typically arrives within 3-7 business days. Local retail fulfillment can occur same-day if stock is available.

Step 6. Follow-up at 4 and 8 weeks. The FDA label and ACOG guidance both recommend reassessing response at 4-8 weeks [1][14]. If a patient has not experienced a meaningful increase in desire or SSEs after 8 weeks of nightly use at 100 mg, discontinuation is recommended.

Pharmacy Access in New Mexico: Retail, Mail-Order, and 503A Compounding

Brand Addyi (flibanserin 100 mg tablets, Sprout Pharmaceuticals) is available at most major retail pharmacies in New Mexico, including chains with locations in Albuquerque, Santa Fe, Las Cruces, and Rio Rancho. Walgreens, CVS, Walmart Pharmacy, and Smith's Pharmacy locations across the state stock or can order Addyi within 1-2 business days.

Mail-order pharmacies, including those affiliated with large pharmacy benefit managers (PBMs), can ship flibanserin to a New Mexico address. Delivery typically takes 3-7 business days after prescription verification. Some mail-order platforms offer 90-day supplies, which reduces the per-unit cost.

New Mexico also permits 503A compounding pharmacies to prepare and dispense flibanserin to individual patients under a valid prescription [15]. A 503A pharmacy compounds for a specific identified patient rather than in bulk, and the compound must be prepared in compliance with USP standards. Compounded flibanserin may appeal to patients who are sensitive to inactive ingredients in the commercial tablet. Patients should confirm that any 503A pharmacy they use holds a current New Mexico Board of Pharmacy license before dispensing [15].

503B outsourcing facilities, by contrast, produce drug products in bulk for healthcare facilities and are not permitted to dispense directly to retail patients without a patient-specific prescription [16]. Most patients accessing flibanserin will use either the brand product or a 503A compound, not a 503B product.

Cost, Insurance, and Prior Authorization in New Mexico

The brand Addyi list price is approximately $800-$900 per month without insurance. Commercial insurance coverage varies widely. Some plans cover Addyi under the pharmacy benefit after prior authorization; others exclude it entirely as a lifestyle drug. New Mexico Medicaid (Centennial Care) does not cover Addyi as of 2025.

Prior authorization (PA) for Addyi typically requires the prescriber to document: (1) a confirmed diagnosis of HSDD using DSM-5 criteria, (2) the absence of a better-explained cause such as a medication side effect or another diagnosable mental health condition, (3) distress scoring consistent with HSDD, and (4) a statement that the patient does not regularly consume alcohol in quantities that would contraindicate flibanserin use [1][2]. Some insurers also require documentation that the patient has tried or been evaluated for psychotherapy (specifically sex therapy or cognitive behavioral therapy) before approving a drug-based intervention.

Sprout Pharmaceuticals offers a savings card program for commercially insured patients that may reduce out-of-pocket cost to as little as $0 per month for eligible patients. Patients should check the current program terms directly with Sprout, as program eligibility rules change periodically.

For uninsured patients or those whose insurance excludes Addyi, GoodRx and similar discount platforms typically show flibanserin 100 mg (30 tablets) at $700-$850 at New Mexico pharmacies, depending on location. Compounded flibanserin through a 503A pharmacy may be meaningfully less expensive, often in the range of $150-$300 per month, though the exact price depends on the pharmacy.

Safety Considerations Specific to the New Mexico Patient Population

The boxed warning for flibanserin states that concurrent use with alcohol can produce severe hypotension and syncope [2]. The FDA label specifies that patients should avoid drinking alcohol at any time during flibanserin treatment, not only within a few hours of dosing. This is the most clinically significant risk to communicate clearly.

Drug interactions are the second major safety concern. Moderate-to-strong CYP3A4 inhibitors, including fluconazole (commonly prescribed for vaginal candidiasis), ketoconazole, clarithromycin, and grapefruit juice, can increase flibanserin plasma concentration to dangerous levels [1]. Because fluconazole is prescribed frequently in women for recurrent yeast infections, providers should advise patients to pause flibanserin for the duration of any short-course azole antifungal course and for 2 days after the last dose [1].

CNS depressants, including benzodiazepines, sleep aids such as zolpidem, and some antihistamines, can potentiate the sedative effects of flibanserin, which is taken at bedtime partly because it causes somnolence in a meaningful proportion of users [2]. The most common adverse effects reported in the three key trials were dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%) [1].

Patients should not drive or operate heavy machinery for at least 6 hours after taking flibanserin, and should avoid night-driving entirely during the initial weeks of treatment [2]. This counseling point is especially relevant for New Mexico patients in rural communities who may commute long distances in low-light conditions.

Transferring an Existing Addyi Prescription to New Mexico

Patients who move to New Mexico from another state and already have an Addyi prescription can transfer it to a New Mexico pharmacy, provided the prescription has remaining refills and the original prescriber held a valid license in the originating state at the time of writing. New Mexico does not require a new evaluation solely because of a state change, as long as the prescription was legally written [8].

If the original prescriber is not licensed in New Mexico and cannot continue to treat the patient across state lines via telehealth, the patient will need a new evaluation with a New Mexico-licensed provider. This is straightforward through a telehealth platform: most platforms complete the intake and consultation within 24-72 hours and can transmit a new prescription to a New Mexico pharmacy the same day the visit is completed.

The DEA's Ryan Haight Online Pharmacy Consumer Protection Act restrictions apply to controlled substances, not to flibanserin, which is unscheduled [17]. This distinction matters because flibanserin transfers and telehealth prescriptions are not subject to the in-person examination requirement that governs Schedule II-IV drugs.

What Patients Say: Clinical Response Expectations

Response to flibanserin is modest on a population level. In the three key trials, women on flibanserin 100 mg nightly reported an increase of approximately 0.5-1.0 SSEs per month above placebo, along with statistically significant improvements in desire and distress scores [1][6]. The FDA acknowledges these are group-level averages, and individual response varies considerably. Some women report marked improvement within 4 weeks; others notice no benefit after 8 weeks and discontinue.

The North American Menopause Society (NAMS) notes in its 2022 position statement on sexual health that flibanserin is appropriate for premenopausal women with generalized HSDD who meet DSM-5 criteria, and that realistic expectation-setting before starting treatment is associated with better adherence [18]. Specifically, NAMS states: "Clinicians should counsel patients that flibanserin produces statistically significant but modest improvements in sexual desire and distress and that individual responses vary substantially" [18].

The American Association of Clinical Endocrinology (AACE) similarly recommends that providers evaluate for and address reversible causes of low libido, including thyroid dysfunction, hyperprolactinemia, and testosterone deficiency (where clinically relevant), before or alongside initiating flibanserin [19]. A serum prolactin level and a TSH can identify two of the most common hormonal contributors to low desire that would not respond to flibanserin [11].

Monitoring After Starting Flibanserin

No mandatory laboratory monitoring is specified in the FDA label once flibanserin is initiated [1]. Clinical follow-up focuses on symptom response and safety.

At 4 weeks: assess for adverse effects (dizziness, somnolence, nausea), confirm alcohol abstinence, and review any new medications for CYP3A4 interactions.

At 8 weeks: formally re-evaluate desire and distress using a validated scale. If the patient does not report a meaningful subjective improvement in the number of SSEs or in desire, the prescriber should recommend discontinuation per FDA label guidance [1]. Continuing a drug with no demonstrated benefit exposes the patient to ongoing side-effect risk without clinical gain.

Beyond 8 weeks: if response is positive, the prescription can continue indefinitely with annual reassessment. Long-term safety data from open-label extension studies showed no new safety signals at 52 weeks of continuous use [1].